Home  About us  Contact
 

Mesylate Therapy (mesylate + therapy)

Distribution by Scientific Domains
Medical Sciences100%

Kinds of Mesylate Therapy

  • imatinib mesylate therapy
    		•

    Selected Abstracts

    Aggressive surgical resection for the management of hepatic metastases from gastrointestinal stromal tumours: a single centre experience

    HPB, Issue 1 2007
    D. Gomez
    Abstract Background: The outcome of surgical intervention for hepatic metastases from gastrointestinal stromal tumours (GIST) is still uncertain. This study evaluated the outcome of patients following aggressive surgical resection and Imatinib mesylate therapy (IM). Patients and methods: This was a retrospective analysis of patients managed with hepatic metastases from GIST over a 13-year period (January 1993 to December 2005). Results: Twelve patients were identified with a median age at diagnosis of 62 (32,78) years. The primary sites of GIST were stomach (n= 5), jejunum (n= 4), sigmoid (n= 1), peritoneum (n= 1) and pancreas (n= 1). Eleven patients underwent surgical resection with curative intent and one patient had cytoreductive surgery. Following surgery with curative intent (n= 11), the overall 2- and 5-year survival rates were both 91%, whereas the 2- and 5-year disease-free rates following primary hepatic resection were 30% and 10%, respectively. The median disease-free period was 17 (3,72) months. Eight patients had recurrent disease and were managed with further surgery (n= 3), radiofrequency ablation (RFA) (n= 2) and IM (n= 8). Overall, there are four patients who are currently disease-free: two patients following initial hepatic resection and two patients following further treatment for recurrent disease. There was no significant association in clinicopathological characteristics between patients with recurrent disease within 2 years and patients who were disease-free for 2 years or more. Overall morbidity was 50% (n= 6), with one postoperative death. The follow-up period was 43 (3,72) months. Conclusion: Surgical resection for hepatic GIST metastases may improve survival in selected patients. Recurrent disease can be managed with surgery, RFA and IM. [source]

    Development of Löffler's endocarditis in FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome despite continuous imatinib mesylate therapy and continuous complete remission,

    AMERICAN JOURNAL OF HEMATOLOGY, Issue 4 2010
    Jan Václavík
    First page of article [source]

    Acute lymphoblastic leukemia without the Philadelphia chromosome occurring in chronic myelogenous leukemia with the Philadelphia chromosome

    AMERICAN JOURNAL OF HEMATOLOGY, Issue 3 2003
    Hee Jin Huh
    Abstract The blast crisis in chronic myelogenous leukemia (CML) is related to the evolution of a Philadelphia chromosome (Ph)-positive clone. Secondary chromosomal abnormalities accompanied by t(9;22) are found in 70,80% of blast crises. Here we describe a patient with Ph-positive CML, who developed Ph-negative acute lymphoblastic leukemia (ALL). A 52-year-old man was diagnosed with CML with the Ph chromosome in the chronic phase. He achieved a partial cytogenetic response after 4 months of imatinib mesylate therapy. After 8 months, common ALL occurred. At that time his karyotype was normal and the Ph chromosome was not noted. Am. J. Hematol. 74:218,220, 2003. © 2003 Wiley-Liss, Inc. [source]

    Cardiac tamponade associated with imatinib mesylate therapy of chronic myelogenous leukemia

    AMERICAN JOURNAL OF HEMATOLOGY, Issue 2 2002
    James C. Barton
    No abstract is available for this article. [source]